Dupixent Lawsuit in South Carolina - Free Case Review

Free Case Review

Start Your Free Review

Answer 2-3 quick questions to review your potential case.

Key Takeaway

South Carolina's growing population of 5.4 million and significant retiree and transplant communities drive an estimated 40,000 Dupixent patients since 2017. The Medical University of South Carolina (MUSC) Hollings Cancer Center in Charleston, an NCI-designated cancer center, provides the state's most advanced cutaneous lymphoma diagnostic capabilities. South Carolina's 3-year SOL provides adequate time, but the state's $350,000 cap on non-economic damages per defendant creates a meaningful limitation on plaintiff recovery. The District of South Carolina has moderate pharmaceutical litigation experience, and the state's jury pools vary significantly by region — Charleston and Columbia tend to be more moderate, while rural areas may be more conservative. South Carolina's Greenville-Spartanburg corridor has seen significant population growth and expanded medical infrastructure, creating additional prescribing volume and potential plaintiff populations.

Written By

People's Justice Legal Research Team

Statute of Limitations

South Carolina: 3 years for product liability (S.C. Code Ann. § 15-3-530(5)). Discovery rule applies — the limitations period begins when the plaintiff discovers or should have discovered the injury and its connection to the product.

3 years from discovery of injury

Filing Venue

Where to File in South Carolina

South Carolina has one federal judicial district — the District of South Carolina, with courthouses in Charleston, Columbia, Greenville, and Florence. South Carolina follows a modified comparative fault system (51 percent bar) and caps non-economic damages at $350,000 per defendant. The state has managed pharmaceutical litigation through its federal courthouse divisions.

South Carolina Data

Exposure in South Carolina

Source: IQVIA prescription data estimates

Source: MUSC Hollings / NCI

Source: S.C. Code Ann. § 15-32-220

FAQ

Frequently Asked Questions

See details below.

Back to Dupixent Lawsuit Lawsuit Overview